|
|
Eli Lilly And Company (LLY) |
|
|
|
| |
LLY's Revenue Growth by Quarter and Year
Eli Lilly And's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| LLY Revenue (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
7,301.80
|
7,999.90
|
7,440.00
|
| III Quarter |
September |
-
|
6,941.60
|
6,772.80
|
5,740.60
|
| II Quarter |
June |
8,312.10
|
6,488.00
|
6,740.10
|
5,499.40
|
| I Quarter |
March |
6,960.00
|
7,810.00
|
6,805.60
|
5,859.80
|
| FY |
|
15,272.10
|
28,541.40
|
28,318.40
|
24,539.80
|
| LLY Revenue second quarter 2023 Y/Y Growth Comment |
Eli Lilly And Company showed record Revenue growth in the second quarter 2023 with 28.11% from the second quarter 2023 2022, to $ 8,312.10 millions.
Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 83 other companies have achieved higher Revenue growth. While Eli Lilly And Company' s Revenue rise of 28.11% ranks overall at the positon no. 663 in the second quarter 2023.
|
| LLY Revenue ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-8.73 % |
7.53 % |
21.69 % |
| III Quarter |
September |
- |
2.49 % |
17.98 % |
4.82 % |
| II Quarter |
June |
28.11 % |
-3.74 % |
22.56 % |
-2.44 % |
| I Quarter |
March |
-10.88 % |
14.76 % |
16.14 % |
15.07 % |
| FY |
|
- |
0.79 % |
15.4 % |
9.95 % |
LLY Revenue (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
5.19 % |
18.12 % |
29.6 % |
| III Quarter |
September |
- |
6.99 % |
0.49 % |
4.39 % |
| II Quarter |
June |
19.43 % |
-16.93 % |
-0.96 % |
-6.15 % |
| I Quarter |
March |
-4.68 % |
-2.37 % |
-8.53 % |
-4.16 % |
| FY (Year on Year) |
|
- |
0.79 % |
15.4 % |
9.95 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 28.11 % |
4.64 % |
-16.76 % |
| (Jun 30 2023) |
|
(June 30. 2014) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 28.11 % |
4.64 % |
-16.76 % |
| (Jun 30 2023) |
|
(June 30. 2014) |
|
| Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Eli Lilly And's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.6 % |
1.53 % |
-28.64 % |
|
|
|
| LLY's II. Quarter Q/Q Revenue Comment |
Eli Lilly And Company achieved in the II. Quarter 2023 above company average sequential Revenue jump of 19.43%, to $ 8,312.10 millions, from $6,960.00 millions in the first quarter.
Eli Lilly And is impressively improving, not only recording higher then normal gain, but also accelerating rate.
Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 622. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.6 % |
1.53 % |
-28.64 % |
|
|
|
| LLY's II. Quarter Q/Q Revenue Comment |
Eli Lilly And Company achieved in the II. Quarter 2023 above company average sequential Revenue jump of 19.43%, to $ 8,312.10 millions, from $6,960.00 millions in the first quarter.
LLY is going from strength to strength, not just recording higher then normal increase, and additionally improving rate.
Within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 622. |
|
Eli Lilly And's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
| Cumulative Revenue 12 Months Ending |
$ 29,515.50 |
$ 27,691.40 |
$ 28,541.40 |
$ 29,239.50 |
$ 29,070.70 |
| Y / Y Revenue Growth (TTM) |
1.53 % |
-5.56 % |
0.79 % |
5.34 % |
8.77 % |
| Year on Year Revenue Growth Overall
Ranking |
# 1686 |
# 122 |
# 960 |
# 491 |
# 2009 |
| Seqeuential Revenue Change (TTM) |
6.59 % |
-2.98 % |
-2.39 % |
0.58 % |
-0.86 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 2397 |
# 3008 |
# 2920 |
# 2399 |
# 2273 |
| Cumulative Revenue growth
Comment |
Although Eli Lilly And's Annual Revenue growth year on year were below company's average 4.58% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.53% year on year, from -5.56% in Mar 31 2023.
In the Healthcare sector 286 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 122 to 1686. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
19.58 % |
4.58 % |
-15.13 % |
| (Sep 30 2021) |
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
19.58 % |
4.58 % |
-15.13 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 137 |
| Sector |
# 384 |
| S&P 500 |
# 2552 |
|
| Cumulative Revenue growth
Comment |
Although Eli Lilly And's Annual Revenue growth year on year were below company's average 4.58% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.53% year on year, from -5.56% in Mar 31 2023.
In the Healthcare sector 286 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 122 to 1686. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
19.58 % |
4.58 % |
-15.13 % |
| (Sep 30 2021) |
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
19.58 % |
4.58 % |
-15.13 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 137 |
| Sector |
# 384 |
| S&P 500 |
# 2552 |
|
48.80%